Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 19/20 | 0.61 |
| ▸ | CHUK | O15111 | 18/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431788 | 0.79 | IKBKB (0.67) | IKBKBCHUK | |
| SCHEMBL14431809 | 0.77 | IKBKB (0.65) | IKBKBCHUK | |
| SCHEMBL14431542 | 0.76 | IKBKB (1.00) | IKBKBCHUK | |
| SCHEMBL14431786 | 0.76 | IKBKB (0.63) | IKBKBCHUK | |
| SCHEMBL14432457 | 0.76 | IKBKB (0.63) | IKBKBCHUK | |
| SCHEMBL14432460 | 0.75 | IKBKB (0.62) | IKBKBCHUK | |
| SCHEMBL5234563 | 0.75 | IKBKB (0.58) | IKBKBCHUK | |
| SCHEMBL5228836 | 0.74 | IKBKB (0.76) | IKBKBCHUK | |
| SCHEMBL14431729 | 0.72 | IKBKB (0.72) | IKBKBCHUK | |
| SCHEMBL5234571 | 0.72 | IKBKB (0.57) | IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490371-B1 | THIOPHENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1490371-A4 | THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6933294-B2 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1490371-A1 | THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040058930-A1 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-25 | — | — | US | disclosed |
| WO-2003084959-A1 | THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058930-A1 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | ABCG2, PFAS, CYP2F1 | IKBKB 2068/4885CHUK 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.